US EditionPublished • loading... • Updated
Because COVID-19 was not enough: 3,625 Biolabs, Nipah Virus Patents, and Self-Amplifying mRNA Injections
Summary by Signs of the Times
Read with caution - this story is only being covered by one news source that has a ‘low factuality’ rating, which means the outlet has a history of poor reporting practices. Learn more about factuality ratings here.1 Articles
1 Articles
Because COVID-19 was not enough: 3,625 Biolabs, Nipah Virus Patents, and Self-Amplifying mRNA Injections
The global expansion of high-containment biolabs without oversight — increasingly engaged in Nipah virus research — combined with aggressive patent consolidation of Nipah's core glycoproteins and their integration into mRNA and self-amplifying mRNA (saRNA) injection platforms, represents a profound and escalating global biosecurity risk. A recent study identified 3,625 Biosafety Level-3 and Level-4 laboratories worldwide: 73% do not publicly dis…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right1Center0Last UpdatedBias Distribution100% Right
Bias Distribution
- 100% of the sources lean Right
100% Right
R 100%
Factuality
To view factuality data please Upgrade to Premium
